Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback